OBJECTIVE: To estimate highly active antiretroviral therapy (HAART)-era incident rates for the first episode of noninfectious conditions in human immunodeficiency virus (HIV)-infected youth in order to identify HAART-era changes in the natural history of perinatal HIV infection. DESIGN: Multicenter prospective cohort study. SETTING: More than 80 sites in the United States including Puerto Rico. PATIENTS: Perinatally HIV-infected youth. MAIN OUTCOME MEASURES: Incidence rates (IRs) per 100 person-years were calculated for targeted noninfectious conditions occurring in perinatally HIV-infected children. A chi(2) test for linear trend was used to evaluate changes in the rates from 2001 to 2006. RESULTS: Two thousand five hundred seventy-five perinatally HIV-infected children (51%, female; 59%, black, non-Hispanic) were enrolled in Pediatric AIDS Clinical Trials Group (PACTG) 219C between 2000 and 2006 and were followed up for a median of 59 months. The 10 most common noninfectious conditions were pregnancy conditions (IR = 6.16; 95% confidence interval (CI), 3.9-9.3), birth defects (IR = 0.19; 95% CI, 0.1-0.3), gynecological dysplasias (IR = 5.92; 95% CI, 3.9-8.6), condyloma (IR = 0.15; 95% CI, 0.1-0.2), encephalopathy (IR = 0.38; 95% CI, 0.3-0.5), pancreatitis (IR = 0.30; 95% CI, 0.2-0.4), cardiac disorders (IR = 0.28; 95% CI, 0.2-0.4), renal disorders (IR = 0.26; 95% CI, 0.2-0.4), peripheral neuropathy (IR = 0.23; 95% CI, 0.2-0.4), and idiopathic thrombocytic purpura (IR = 0.15; 95% CI, 0.1-0.3). Among these conditions, 5 showed significant trends, with IRs increasing over time in pregnancy-related conditions (P < .001) and gynecological dysplasias (P = .02) while IRs decreased over time for encephalopathy (P < .001), pancreatitis (P = .002), and cardiac disorders (P = .007). CONCLUSIONS: Between 2001 and 2006, the incidence for 3 conditions decreased and increased for 2 others, demonstrating the change in medical issues and conditions in perinatally infected youth. Continued surveillance with appropriate tools will be needed to assess the long-term effects of HAART and HIV as well as development of new noninfectious conditions of HIV.
OBJECTIVE: To estimate highly active antiretroviral therapy (HAART)-era incident rates for the first episode of noninfectious conditions in humanimmunodeficiency virus (HIV)-infected youth in order to identify HAART-era changes in the natural history of perinatal HIV infection. DESIGN: Multicenter prospective cohort study. SETTING: More than 80 sites in the United States including Puerto Rico. PATIENTS: Perinatally HIV-infected youth. MAIN OUTCOME MEASURES: Incidence rates (IRs) per 100 person-years were calculated for targeted noninfectious conditions occurring in perinatally HIV-infectedchildren. A chi(2) test for linear trend was used to evaluate changes in the rates from 2001 to 2006. RESULTS: Two thousand five hundred seventy-five perinatally HIV-infectedchildren (51%, female; 59%, black, non-Hispanic) were enrolled in Pediatric AIDS Clinical Trials Group (PACTG) 219C between 2000 and 2006 and were followed up for a median of 59 months. The 10 most common noninfectious conditions were pregnancy conditions (IR = 6.16; 95% confidence interval (CI), 3.9-9.3), birth defects (IR = 0.19; 95% CI, 0.1-0.3), gynecological dysplasias (IR = 5.92; 95% CI, 3.9-8.6), condyloma (IR = 0.15; 95% CI, 0.1-0.2), encephalopathy (IR = 0.38; 95% CI, 0.3-0.5), pancreatitis (IR = 0.30; 95% CI, 0.2-0.4), cardiac disorders (IR = 0.28; 95% CI, 0.2-0.4), renal disorders (IR = 0.26; 95% CI, 0.2-0.4), peripheral neuropathy (IR = 0.23; 95% CI, 0.2-0.4), and idiopathic thrombocytic purpura (IR = 0.15; 95% CI, 0.1-0.3). Among these conditions, 5 showed significant trends, with IRs increasing over time in pregnancy-related conditions (P < .001) and gynecological dysplasias (P = .02) while IRs decreased over time for encephalopathy (P < .001), pancreatitis (P = .002), and cardiac disorders (P = .007). CONCLUSIONS: Between 2001 and 2006, the incidence for 3 conditions decreased and increased for 2 others, demonstrating the change in medical issues and conditions in perinatally infected youth. Continued surveillance with appropriate tools will be needed to assess the long-term effects of HAART and HIV as well as development of new noninfectious conditions of HIV.
Authors: Sharon Nachman; Philimon Gona; Wayne Dankner; Adrianna Weinberg; Ram Yogev; Anne Gershon; Mobeen Rathore; Jennifer S Read; Sharon Huang; Carol Elgie; Kim Hudgens; Walter Hughes Journal: Pediatrics Date: 2005-03-16 Impact factor: 7.124
Authors: S L Gortmaker; M Hughes; J Cervia; M Brady; G M Johnson; G R Seage; L Y Song; W M Dankner; J M Oleske Journal: N Engl J Med Date: 2001-11-22 Impact factor: 91.245
Authors: B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti Journal: JAMA Date: 1999-12-15 Impact factor: 56.272
Authors: Janice K Louie; Ling Chin Hsu; Dennis H Osmond; Mitchell H Katz; Sandra K Schwarcz Journal: J Infect Dis Date: 2002-09-13 Impact factor: 5.226
Authors: D M Finkelstein; P L Williams; G Molenberghs; J Feinberg; W G Powderly; J Kahn; R Dolin; D Cotton Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1996-05-01
Authors: M Culnane; M Fowler; S S Lee; G McSherry; M Brady; K O'Donnell; L Mofenson; S L Gortmaker; D E Shapiro; G Scott; E Jimenez; E C Moore; C Diaz; P M Flynn; B Cunningham; J Oleske Journal: JAMA Date: 1999-01-13 Impact factor: 56.272
Authors: Gayatri Mirani; Paige L Williams; Miriam Chernoff; Mark J Abzug; Myron J Levin; George R Seage; James M Oleske; Murli U Purswani; Rohan Hazra; Shirley Traite; Bonnie Zimmer; Russell B Van Dyke Journal: Clin Infect Dis Date: 2015-08-12 Impact factor: 9.079
Authors: Murli U Purswani; Miriam C Chernoff; Charles D Mitchell; George R Seage; Gaston Zilleruelo; Carolyn Abitbol; Warren A Andiman; Kathleen A Kaiser; Hans Spiegel; James M Oleske Journal: Pediatr Nephrol Date: 2012-02-26 Impact factor: 3.714
Authors: Anne M Neilan; Brad Karalius; Kunjal Patel; Russell B Van Dyke; Mark J Abzug; Allison L Agwu; Paige L Williams; Murli Purswani; Deborah Kacanek; James M Oleske; Sandra K Burchett; Andrew Wiznia; Miriam Chernoff; George R Seage; Andrea L Ciaranello Journal: JAMA Pediatr Date: 2017-05-01 Impact factor: 16.193
Authors: Charles D Mitchell; Miriam C Chernoff; George R Seage; Murli U Purswani; Hans M L Spiegel; Gaston Zilleruelo; Carolyn Abitbol; Barbara Heckman; Christopher B Ponce; James M Oleske Journal: Pediatr Nephrol Date: 2014-08-24 Impact factor: 3.714
Authors: Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Flávia Vanesca Felix Leão; Regina Célia de Menezes Succi; Daisy Maria Machado; Aída de Fátima Thomé Barbosa Gouvêa; Fabiana Bononi do Carmo; Suenia Vasconcelos Beltrão; Maria Aparecida de Paula Cançado; João Tomas de Abreu Carvalhaes Journal: Pediatr Nephrol Date: 2015-12-04 Impact factor: 3.714